Semaglutide

Overview

The most heavily studied peptide in modern medicine. Semaglutide mimics the gut hormone GLP-1, slowing gastric emptying, amplifying glucose-dependent insulin release, and acting on hypothalamic appetite circuits. Phase 3 programs enrolling tens of thousands of patients support both glycemic and weight outcomes.

How it works

Binds the GLP-1 receptor on pancreatic beta cells, gastric smooth muscle, and hypothalamic/hindbrain neurons. The result is glucose-dependent insulin secretion, suppressed glucagon, delayed gastric emptying, and reduced hunger and food reward signalling. Acylation with a C18 diacid chain gives albumin binding and a one-week half-life.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

• More than 15 phase 3 trials with hard clinical endpoints, not just surrogate markers.
• Cardiovascular and kidney benefits are event-driven — the strongest evidence class available.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Substantial, durable weight loss Strong evidence

  In the 68-week STEP 1 trial, adults without diabetes lost roughly 15% of body weight on 2.4 mg weekly versus about 2.4% on placebo — a magnitude previously seen only with bariatric surgery.

• Strong glycemic control Strong evidence

  HbA1c reductions on the order of 1.5–1.8 percentage points across the SUSTAIN trials, with low intrinsic hypoglycemia risk because insulin release is glucose-dependent.

• Cardiovascular event reduction Strong evidence

  The SELECT trial in patients with obesity and established cardiovascular disease but no diabetes showed roughly a 20% relative reduction in major adverse cardiovascular events.

• Kidney outcome benefit Strong evidence

  The FLOW trial in diabetic kidney disease was stopped early for efficacy on a composite kidney endpoint.

• Symptom relief in HFpEF Moderate evidence

  STEP-HFpEF showed clinically meaningful improvement in heart-failure symptom scores and 6-minute walk distance in obesity-related HFpEF.

• Reduction in liver fat Moderate evidence

  Trials in metabolic dysfunction-associated steatohepatitis show improved steatosis and inflammation, though fibrosis benefit has been harder to demonstrate.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• Gastrointestinal intolerance Moderate evidence

  Nausea, vomiting, diarrhea and constipation affect a large minority of users — the single most common reason for stopping. Slow titration mitigates but does not eliminate it.

• Thyroid C-cell tumor boxed warning Serious

  Rodents developed medullary thyroid tumors. Human relevance is unproven, but the drug is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.

• Pancreatitis and gallbladder disease Serious

  Acute pancreatitis is uncommon but reported. Rapid weight loss raises the rate of cholelithiasis and cholecystitis.

• Loss of lean mass Moderate evidence

  A meaningful share of total weight lost is fat-free mass. Resistance training and adequate protein intake are standard mitigation, not optional extras.

• Delayed gastric emptying and anesthesia risk Moderate evidence

  Retained gastric contents have prompted anesthesia societies to issue pre-procedural fasting and withholding guidance because of aspiration risk.

• Retinopathy worsening with rapid glycemic drop Moderate evidence

  Observed in SUSTAIN-6 in patients with pre-existing diabetic retinopathy on insulin; requires ophthalmologic monitoring in that group.

• Compounded and counterfeit supply Serious

  FDA has repeatedly warned about compounded "semaglutide salts" and counterfeit pens with incorrect content, unsafe dosing instructions, and non-sterile preparation.

• Weight regain on discontinuation Moderate evidence

  The STEP 1 extension found most lost weight returned within a year of stopping. It is a maintenance therapy, not a course of treatment.

Who should avoid it

• Personal or family history of medullary thyroid carcinoma or MEN2
• Prior pancreatitis (relative)
• Pregnancy and breastfeeding
• Type 1 diabetes as monotherapy
• Active gastroparesis

If used under medical supervision, monitor

• HbA1c and fasting glucose
• Weight and body composition
• Renal function during vomiting/diarrhea
• Dilated eye exam in pre-existing retinopathy
• Lipase only if symptomatic

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

• Insulin and sulfonylureas — dose reduction usually required to avoid hypoglycemia
• All oral medications — delayed gastric emptying alters absorption; matters most for narrow-therapeutic-index drugs such as levothyroxine and warfarin
• Anesthesia — societies advise withholding before elective procedures because of retained gastric contents and aspiration risk
• Alcohol — compounds nausea and hypoglycemia risk

Commonly confused with

These mix-ups cause real harm — two products sold under one name, or two molecules whose effects run in opposite directions.

Regulatory & legal status

Prescription drug. Compounded versions are permitted only under specific FDA conditions, which have narrowed as shortages resolved. Peptides sold online as "research semaglutide" are unapproved and unverified.

Infographic

Semaglutide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Semaglutide
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials
• DailyMed — official FDA prescribing information

Related peptides in Metabolic & Weight